OJVM> Vol.4 No.2, February 2014

Electroencephalographic Recordings in the Canine: Effects of Low Dose Medetomidine or Dexmedetomidine Followed by Atipamezole

DownloadDownload as PDF (Size:1062KB)  HTML    PP. 7-13  

ABSTRACT

Objectives: 1) To describe electroencephalogram (EEG) appearance in the awake dog and compare these results with EEG recordings after low dose medetomidine (2 μg/kg IV) followed by atipamezole (10 μg/kg, IM); 2) To institute EEG recordings after low dose medetomidine or dexmedetomidine as a standard of practice if focal abnormalities and amplitudes were not significantly altered by pharmaceuticals in Phase 1 of this study. Methods: Electroencephalograms were performed on eight clinical canine patients with suspected intracranial disease involving the prosencephalon. A five lead montage was used to record the EEGs. Each dog had an awake, baseline recording followed by an EEG performed after administration of low dose medetomidine (2 μg/kg IV) then atipamezole (10 μg/kg, IM). In the second phase of this study, the same dose of medetomidine or dexmedetomidine at 1 μg/kg IV and atipamezole (10 μg/kg, IM) were used in the evaluation of 20 clinical patients with suspected neurologic disease. Results: In Phase 1, awake recordings were laced with movement artifacts. After medetomidine and atipamezole, EEG waveforms were slower. Following atipamezole, however, the frequencies were observed to increase with time. Statistical evaluation revealed significantly more artifacts in baseline recordings. No statistically significant change was observed in focal abnormalities or amplitude. In Phase 2, the a2-adrenoreceptor agonists followed by atipamezole without the use of lidocaine produced clinically reliable results. Clinical Significance: Quality and diagnostic electroencephalogram (EEG) recordings are frequently inconvenient to obtain in the awake dog. Movement results in artifacts and dislodged leads. Administration of low dose medetomidine or dexmedetomidine followed by atipamezole reliably reduced the impact of movement artifacts and produced clinically valid EEG recordings in dogs.

Cite this paper

L. Tepper and A. Shores, "Electroencephalographic Recordings in the Canine: Effects of Low Dose Medetomidine or Dexmedetomidine Followed by Atipamezole," Open Journal of Veterinary Medicine, Vol. 4 No. 2, 2014, pp. 7-13. doi: 10.4236/ojvm.2014.42002.

References

[1] J. M. Ducoté and C. W. Dewey, “Neurodiagnostic,” In: C. W. Dewey, Ed., A Practical Guide to Canine and Feline Neurology, Blackwell Publishing, Ames, 2003, pp. 99-178.
http://dx.doi.org/10.1111/j.1467-2995.2005.00221.x
[2] P. A. March and W. W. Muir, “Bispectral Analysis of the Electroencephalogram: A Review of Its Development and Use in Anesthesia,” Veterinary Anaesthesia and Analgesia, Vol. 32, No. 5, 2005, pp. 241-255.
[3] H. S. Jang, Y. S. Kwon, M. G. Lee, et al., “The Effect of Tiletamine/Zolazepam (Zoletile) Combination with Xylazine or Medetomidine on Electroencephalograms in Dogs,” The Journal of Veterinary Medical Science, Vol. 66, No. 5, 2004, pp. 501-507.
http://dx.doi.org/10.1292/jvms.66.501
[4] D. Stenberg, “Physiological Role of Alpha 2-Adrenoceptors in the Regulation of Vigilance and Pain: Effect of Medetomidine,” Acta Veterinaria Scandinavica. Supplementum, Vol. 85, 1989, pp. 21-28.
[5] M. D. Lorenz and J. N. Kornegay, “Seizures, Narcolepsy and Cataplexy,” In: M. D. Lorenz and J. N. Kornegay, Eds., Handbook of Veterinary Neurology, 4th Edition, Saunders, St. Louis, 2004, pp. 323-339.
[6] R. W. Redding, R. B. Prynn and J. L. Wagner, “Clinical Use of the Electroencephalogram in Canine Encephalitis,” American Veterinary Medical Association, Vol. 148, 1966, pp. 141-149.
[7] N. Lemo, D. Vnuk, B. Radisic, et al., “Determination of the Toxic Dose of Lidocaine in Dogs and Its Corresponding Serum Concentration,” Veterinary Record, Vol. 160, No. 11, 2007, pp. 374-375.
http://dx.doi.org/10.1136/vr.160.11.374
[8] W. B. Pickworth, L. G. Sharpe and V. N. Gupta, “Morphine-Like Effects of Clonidine on the EEG, Slow Wave Sleep and Behavior in the Dog,” European Journal of Pharmacology, Vol. 81, No. 4, 1982, pp. 551-557.
http://dx.doi.org/10.1016/0014-2999(82)90344-2
[9] K. Itamoto, Y. Taura, N. Wada, et al., “Effect of Medetomidine on Electroencephalography and Use of a Quantitative Electroencephalograph for Evaluating Sedation Levels in Dogs,” Journal of Veterinary Medicine Series A, Vol. 48, No. 9, 2001, pp. 525-535.
http://dx.doi.org/10.1046/j.1439-0442.2001.00381.x
[10] R. Virtanen, “Pharmacological Profiles of Medetomidine and Its Antagonist, Atipamezole,” Acta Veterinaria Scandinavica, Vol. 85, 1989, pp. 29-37.
[11] A. Pitkänen, S. Narkilahti, Z. Bezvenyuk, et al., “Atipamezole, an Alpha(2)-Adrenoceptor Antagonist, Has Disease Modifying Effects on Epileptogenesis in Rats,” Epilepsy Research, Vol. 61, No. 1-3, 2004, pp. 119-140.
http://dx.doi.org/10.1016/j.eplepsyres.2004.07.005
[12] M. D. Sinclair, “A Review of the Physiological Effects of Alpha2-Agonists Related to the Clinical Use of Medetomidine in Small Animal Practice,” The Canadian Veterinary Journal, Vol. 44, No. 11, 2003, pp. 885-897.
[13] C. E. Short, “Alpha 2 Agents in Animals,” In: C. E. Short, Ed., Alpha 2 Agents in Animals Sedation, Analgesia and Anaesthesia, Vol. 1, Veterinary Practice Publishing, Santa Barbara, 1992, pp. 1-55.
[14] O. Vainio and T. Vaha-Vahe, “Reversal of Medetomidine Sedation by Atipamezole in Dogs,” Journal of Veterinary Pharmacology and Therapeutics, Vol. 13, 1990, pp. 15-22.
http://dx.doi.org/10.1111/j.1365-2885.1990.tb00742.x

comments powered by Disqus

Copyright © 2014 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.